A metabolome-wide Mendelian randomization study prioritizes potential causal circulating metabolites for multiple sclerosis.

Angela Ge, Yitang Sun, Thaddaeus Kiker, Yanjiao Zhou, Kaixiong Ye
Author Information
  1. Angela Ge: Lower Merion High School, Ardmore, PA, USA; Department of Genetics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA, USA.
  2. Yitang Sun: Department of Genetics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA, USA.
  3. Thaddaeus Kiker: Department of Genetics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA, USA; Sunny Hills High School, Fullerton, CA, USA.
  4. Yanjiao Zhou: Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA.
  5. Kaixiong Ye: Department of Genetics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA, USA; Institute of Bioinformatics, University of Georgia, Athens, GA, USA. Electronic address: Kaixiong.Ye@uga.edu.

Abstract

To prioritize circulating metabolites that likely play causal roles in the pathogenesis of multiple sclerosis (MS). Two-sample Mendelian randomization analysis was performed to estimate the causal effects of 571 circulating metabolites on the risk of MS. Genetic instruments for circulating metabolites were obtained from three previous genome-wide association studies (GWAS) of the blood metabolome (N = 7824; 24,925; and 115,078; respectively), while genetic associations with MS were from a large GWAS by the International Multiple Sclerosis Genetics Consortium (14,802 cases and 26,703 control). The primary analysis was performed with the multiplicative random-effect inverse variance-weighted method, while multiple sensitivity analyses were conducted with the weighted median, weighted mode, MR-Egger, and MR-PRESSO. A total of 29 metabolites had suggestive evidence of causal associations with MS. Genetically instrumented levels of serine (OR = 1.56, 95% CI = 1.25-1.95), lysine (OR = 1.18, 95% CI = 1.01-1.38), acetone (OR = 2.45, 95% CI = 1.02-5.90), and acetoacetate (OR = 2.47, 95% CI = 1.14-5.34) were associated with a higher MS risk. Total cholesterol and phospholipids in large very-low-density lipoprotein were associated with a lower MS risk (OR = 0.83, 95% CI = 0.69-1.00; OR = 0.80, 95% CI = 0.68-0.95), but risk-increasing associations (OR = 1.20, 95% CI = 1.04-1.40; OR = 1.13, 95% CI = 1.00-1.28) were observed for the same two lipids in very large high-density lipoprotein. Our metabolome-wide Mendelian randomization study prioritized a list of circulating metabolites, such as serine, lysine, acetone, acetoacetate, and lipids, that likely have causal associations with MS.

Keywords

References

  1. Sci Transl Med. 2012 Jun 6;4(137):137ra73 [PMID: 22674551]
  2. Cell Mol Life Sci. 2021 Apr;78(7):3181-3203 [PMID: 33449145]
  3. PLoS Biol. 2022 Feb 25;20(2):e3001547 [PMID: 35213538]
  4. Brain Commun. 2021 Oct 12;3(4):fcab240 [PMID: 34755110]
  5. PLoS Genet. 2017 Nov 17;13(11):e1007081 [PMID: 29149188]
  6. Nat Commun. 2016 Mar 23;7:11122 [PMID: 27005778]
  7. Stat Med. 2015 Sep 20;34(21):2926-40 [PMID: 25950993]
  8. J Neuroimmunol. 2018 Jan 15;314:94-100 [PMID: 29224959]
  9. Genet Epidemiol. 2013 Nov;37(7):658-65 [PMID: 24114802]
  10. Genet Epidemiol. 2016 May;40(4):304-14 [PMID: 27061298]
  11. Sci Rep. 2018 Nov 19;8(1):17026 [PMID: 30451923]
  12. Nat Rev Neurol. 2017 Jan;13(1):25-36 [PMID: 27934854]
  13. J Neurol. 2021 Jan;268(1):114-124 [PMID: 32728946]
  14. Cell Metab. 2019 Sep 3;30(3):539-555.e11 [PMID: 31257153]
  15. JCI Insight. 2017 Oct 5;2(19): [PMID: 28978801]
  16. BMJ. 2018 Jul 12;362:k601 [PMID: 30002074]
  17. Nat Genet. 2014 Jun;46(6):543-550 [PMID: 24816252]
  18. Eur J Epidemiol. 2017 May;32(5):377-389 [PMID: 28527048]
  19. Int J Epidemiol. 2017 Dec 1;46(6):1985-1998 [PMID: 29040600]
  20. Elife. 2018 May 30;7: [PMID: 29846171]
  21. Neurol Neuroimmunol Neuroinflamm. 2020 Jan 14;7(2): [PMID: 31937597]
  22. Neurol Neuroimmunol Neuroinflamm. 2015 Dec 24;3(1):e185 [PMID: 26740964]
  23. Brain Res. 2020 Apr 1;1732:146589 [PMID: 31816317]
  24. Mult Scler. 2021 Oct;27(11):1799-1802 [PMID: 33605804]
  25. Mult Scler. 2020 Apr;26(5):591-598 [PMID: 31965880]
  26. Int J Epidemiol. 2015 Apr;44(2):512-25 [PMID: 26050253]
  27. Nat Genet. 2018 May;50(5):693-698 [PMID: 29686387]
  28. Nat Chem Biol. 2018 Jan;14(1):22-28 [PMID: 29131145]
  29. Mult Scler. 2021 Nov;27(13):2077-2084 [PMID: 33591230]
  30. Autoimmun Rev. 2022 Jun;21(6):103088 [PMID: 35398271]
  31. J Clin Neurol. 2022 Sep;18(5):529-534 [PMID: 36062770]
  32. Int J Epidemiol. 2011 Jun;40(3):740-52 [PMID: 20813862]
  33. Mol Neurobiol. 2017 Nov;54(9):7520-7533 [PMID: 27826747]
  34. Wellcome Open Res. 2020 Oct 22;5:252 [PMID: 33381656]
  35. Endocrinol Metab Clin North Am. 2022 Sep;51(3):437-458 [PMID: 35963623]
  36. Mult Scler. 2014 Apr;20(5):558-65 [PMID: 24080986]
  37. Adv Nutr. 2022 Oct 2;13(5):2002-2014 [PMID: 35679067]
  38. PLoS One. 2017 Jul 26;12(7):e0181758 [PMID: 28746356]
  39. Front Genet. 2020 Mar 30;11:254 [PMID: 32292418]
  40. Mult Scler. 2021 Dec;27(14):2150-2158 [PMID: 33749377]
  41. Mult Scler. 2021 Nov;27(13):1994-2000 [PMID: 33605807]
  42. Neurology. 2023 Oct 24;101(17):e1729-e1740 [PMID: 37657941]
  43. Front Immunol. 2022 Mar 21;13:834644 [PMID: 35386698]

Grants

  1. R35 GM143060/NIGMS NIH HHS

MeSH Term

Humans
Acetoacetates
Acetone
Genome-Wide Association Study
Lysine
Mendelian Randomization Analysis
Multiple Sclerosis
Metabolome
Serine
Polymorphism, Single Nucleotide

Chemicals

acetoacetic acid
Acetoacetates
Acetone
Lysine
Serine

Word Cloud

Created with Highcharts 10.0.095%MSmetabolitesCI = 1circulatingcausalMendelianrandomizationassociationsOR = 1multiplesclerosisrisklargelikelyanalysisperformedGWASMultipleweightedserine95lysineacetoneOR = 2acetoacetateassociatedlipoproteinOR = 0CI = 0lipidsmetabolome-widestudyprioritizeplayrolespathogenesisTwo-sampleestimateeffects571Geneticinstrumentsobtainedthreepreviousgenome-wideassociationstudiesbloodmetabolomeN = 782424925115078respectivelygeneticInternationalSclerosisGeneticsConsortium14802cases26703controlprimarymultiplicativerandom-effectinversevariance-weightedmethodsensitivityanalysesconductedmedianmodeMR-EggerMR-PRESSOtotal29suggestiveevidenceGeneticallyinstrumentedlevels5625-11801-1384502-5904714-534higherTotalcholesterolphospholipidsvery-low-densitylower8369-1008068-0risk-increasing2004-1401300-128observedtwohigh-densityprioritizedlistprioritizespotentialMetabolitesMetabolome

Similar Articles

Cited By